Tag: Progenics Pharmaceuticals
August 6, 2019
CMS Grants Progenics New Technology Add-On Payment for Inpatient Use of AZEDRA
Progenics Pharmaceuticals (NASDAQ:PGNX) has announced that the Centers for Medicare & Medicaid Services (CMS) approved a new technology add-on payment... June 20, 2019
Progenics Pharmaceuticals to Initiate a Basket Trial
Progenics Pharmaceuticals (NASDAQ:PGNX) has announced it has reached a decision with the US Food and Drug Administration (FDA) on plans... June 13, 2019
Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy
Progenics Pharmaceuticals (NASDAQ:PGNX) has announced the first patient in its Phase 2 clinical trial studying I-131 1095 radiotherapy has been... May 14, 2019
Progenics Pharmaceuticals and ROTOP Pharmaka GmbH Announce European Collaboration
Progenics Pharmaceuticals (NASDAQ:PGNX) has announced an exclusive agreement with ROTOP Pharmaka GmbH to develop and commercialize Progenics’ 1404 prostate specific... February 11, 2019
Progenics Acquires AZEDRA® (iobenguane I 131) Radiopharmaceutical Manufacturing Facility
Progenics Pharmaceuticals (NASDAQ:PGNX) has announced it has acquired a manufacturing facility for AZEDRA for cash consideration of US$8 million. AZEDRA...
October 15, 2018
Biotech Update: Q3 2018 in Review
With the first three quarters of 2018 over, the Investing News Network is reviewing top news in the biotech space... October 5, 2018